[Bendotiamine efficacy in alcoholic polyneuropathy therapy].
Benfogamma efficacy in alcoholic polyneuropathy therapy with pain syndrome and other sensor disorders has been studied. Fourteen males with stage II-III chronic alcoholism (mean age 41.2 +/- 9 years, mean alcoholism duration 20.6 +/- 6 years, mean alcoholic polyneuropathy therapy duration 6.8 +/- 4.9 years) have been examined, 93% of the cases having positive family history of alcoholism. Clinical neurophysiological examination was conducted at the beginning and at the end of 6-week therapy, 450 mg/day (2 weeks) and 300 mg/day (4 weeks). During the treatment the regress of algic, other sensor and movement disorders, as well as some neuropathy symptoms has been observed. The evidence of positive dynamics at peripheral and segmental nerve system level was supported by neurophysiological data.
Anisimova
E I
EI
Danilov
A B
AB
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D020269:Alcoholic Neuropathy / Q000188:drug therapy*; D002908:Chronic Disease; D006801:Humans; D008297:Male; D012720:Severity of Illness Index; D013831:Thiamine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D013831:Thiamine; C013835:benphothiamine